Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lytix Biopharma AS ( (DE:6BG) ) has shared an announcement.
Lytix Biopharma AS held its annual general meeting on 14 April 2026, where shareholders approved all proposed resolutions, underscoring support for the company’s current strategy and governance. The general meeting elected a streamlined Board of Directors for a uniform two-year term to 2028, reducing the board from seven to six members and appointing Eric Falcand as chair alongside five other directors.
The company expressed gratitude to outgoing board member Kjetil Hestdal for his contributions since 2021, highlighting his role in Lytix’s recent development phase. Shareholders also granted a new board authorization to increase share capital in connection with the company’s option program, replacing the previous mandate and providing continued flexibility in incentivizing employees and aligning long-term interests.
More about Lytix Biopharma AS
Lytix Biopharma AS is a clinical-stage biotechnology company based in Oslo, Norway, focused on developing a highly differentiated oncolytic molecule platform derived from host-defense peptides. Its lead product, ruxotemitide, is a first-in-class oncolytic molecule aimed at enabling durable anti-cancer immunity across multiple cancer indications, both as monotherapy and in combination regimens.
The company maintains a pipeline of oncology candidates targeting various treatment settings and is listed on Euronext Growth Oslo under the ticker LYTIX. Its strategy centers on leveraging novel immuno-oncology mechanisms to strengthen its position in the competitive cancer therapeutics market.
Average Trading Volume: 60,848
Current Market Cap: NOK826.7M
For an in-depth examination of 6BG stock, go to TipRanks’ Overview page.